Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market - Seite 2

Biotechnologie and Bioventure on this transaction.

About Jennewein Biotechnologie GmbH

Jennewein Biotechnologie is a leading international industrial biotechnology
company with a range of products in the field of human milk oligosaccharides
(HMOs) and rare monosaccharides such as L-Fucose and Sialic acid. The company
manufactures an extensive portfolio of innovative HMO products, such as 2?
fucosyllactose, 3?-fucosyllactose, Lacto-N-neotetraose, and lacto-N-tetraose.
These rare sugars are used in the food industry (particularly infant milk
formulas), the pharmaceutical industry, and the cosmetic industry. Jennewein
Biotechnologie GmbH was founded in 2005 in Bonn and is headquartered in
Rheinbreitbach (Rheinland-Pfalz).

About Chr. Hansen

Chr. Hansen is a leading, global bioscience company that develops natural
ingredient solutions for the food, nutritional, pharmaceutical and agricultural
industries. We develop and produce cultures, enzymes, probiotics and natural
colors for a rich variety of foods, confectionery, beverages, dietary
supplements and even animal feed and plant protection. Our product innovation is
based on around 40,000 microbial strains - we like to refer to them as 'good
bacteria'. Our solutions enable food manufacturers to produce more with less -
while also reducing the use of chemicals and other synthetic additives - which
make our products highly relevant in today's world. Sustainability is an
integral part of Chr. Hansen's vision to improve food and health. In 2019 Chr.
Hansen was ranked as the world's most sustainable company by Corporate Knights
thanks to our strong sustainability efforts and our many collaborative
partnerships with our customers. We have been delivering value to our partners -
and, ultimately, end consumers worldwide - for over 140 years. We are proud that
more than one billion people consume products containing our natural ingredients
every day.

For further information please contact:

Bettina Gutiérrez, Press and Public Relations Jennewein Biotechnologie GmbH,
Tel:+ 49 2224 98810797
Martin Riise, Head of Investor Relations Chr. Hansen Holding S/A, Tel: +45 5339
2250
Annika Stern, Investor Relations Officer Chr. Hansen Holding S/A, Tel: +45 2399
2382
Camilla Lercke, Head of Media Relations Chr. Hansen Holding S/A, Tel: +45 5339
2384

Additional content: http://presseportal.de/pm/77411/4714059
OTS: Jennewein Biotechnologie GmbH